Researchers find common ALS gene target affected by multiple protein disruptions.
A research group from Tohoku University and Keio University has found a shared pattern in the way amyotrophic lateral sclerosis (ALS) develops, which could lead to better treatments. ALS is a serious condition that causes the gradual breakdown of nerve cells responsible for controlling movement. Over time, muscles weaken, and simple tasks such as speaking, eating, or breathing become more difficult. What makes this disease especially tough to treat is how different it looks from person to person. Many forms of ALS involve separate triggers, which has made it hard to find a common path toward treatment, until now, after researchers found an answer to ALS gene suppression.
The researchers studied four different proteins known to play a role in ALS. These proteins, when not working correctly, disturb the process by which cells handle their RNA, the blueprint that tells cells how to make proteins. Even though each protein malfunctioned in a different way, the scientists discovered that all cases led to the same result: a drop in the levels of a gene called UNC13A. This gene helps nerve cells communicate, and without it, the entire system starts to break down.
In digging deeper, the team found two reasons why UNC13A levels were dropping. The first reason involved a kind of glitch in the RNA instructions that caused the message to fall apart before it could be used. The second reason was more surprising. A protein called REST, which normally keeps genes in check, became too active when certain ALS-related proteins were missing. This overactive REST turned down the UNC13A gene, leading to gene suppression and keeping it from doing its job. The team had never seen this second reason before and believes it could explain some of the shared symptoms across different ALS cases.
To see whether these changes were actually happening in people with ALS, the researchers examined motor neurons made from stem cells taken from ALS patients. They also looked at tissue samples from those who had died from the disease. In both cases, the signs were there: high levels of REST and lower activity from UNC13A. This connection was not just something that happened in the lab. It showed up in real people with ALS. That gives the findings more weight and could guide future drug development.
What makes this discovery stand out is how it links different causes of ALS to the same gene suppression. That shared link, UNC13A getting turned off, may give scientists a place to start when trying to create treatments that work for more patients, not just those with one specific kind of ALS. If UNC13A can be protected, or if REST activity can be kept in check, the downward spiral of the disease might be slowed or stopped.
ALS has long been a mystery because of how many different things can go wrong in the body to cause it. Treatments have been hard to develop because they often only target one piece of the puzzle. This new research offers a possible way to reach many pieces at once. It may not solve everything, but it could bring science closer to treatments that help more people live longer and better. For those watching loved ones go through ALS, any step forward brings a measure of hope that has been long overdue.
Sources:
New research identifies critical gene for treatment
ALS-associated RNA-binding proteins promote UNC13A transcription through REST downregulation
Join the conversation!